-
Product Insights
Lung Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ...
-
Sector Analysis
Alpha-1 Antitrypsin Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Alpha-1 Antitrypsin Deficiency Market Report Overview The Alpha-1 Antitrypsin Deficiency (AATD) market size in the 2MM (US and Germany) was valued at $1.36 billion in 2021 and is forecast to grow at a CAGR of more than 12% during the forecast period, 2021-2031. The introduction of 4 new pipeline agents are key drivers of this market growth. AATD is an inherited disease that causes an increased risk of chronic obstructive pulmonary disorder (COPD), hepatic failure, skin problems (panniculitis), and inflammation...
-
Sector Analysis
Pancreatic Cancer – Opportunity Analysis and Forecasts to 2029
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses. The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals
The pharmaceutical and healthcare industry recorded a decrease in the number of number deals and deal values in 2016 with 4,325 deals worth USD447.3 billion, as compared to 4,971 deals worth USD601.9 billion in 2015. The oncology market recoded 1,437 deals in 2016, as compared to 1,505 deals in 2015. North America reported a decrease in the number of deals in 2016 with 2,852 deals, as compared to 3,181 deals in 2015. Licensing agreements recorded an increase in the receipt...
-
Sector Analysis
PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026
Hemophilia A and B are rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, and are characterized by the failure of blood to form normal clots after damage to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing...
-
Sector Analysis
Competitor Landscape: Lupus
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...
-
Product Insights
Thrombophilia Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Thrombophilia Global Clinical Trials Review, H1, 2016" provides an overview of Thrombophilia clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombophilia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2016. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2016. The report portrays detailed comparative data on the number of deals and their value in the last...